BIOENVISION INC 4

Accession 0000950142-04-004523

CIK 0001028205operating

View on SEC.gov Company Profile

Filed

Dec 22, 7:00 PM ET

Accepted

Dec 23, 12:35 PM ET

Size

58.8 KB

Accession

0000950142-04-004523

Insider Transaction Report

Form 4

Period: 2004-12-22

BIOENVISION INCBIVN

PERSEUS SOROS PARTNERS LLC

10% OwnerOther

Transactions

Sale
Common Stock
2004-12-22$8.53/sh−52$444→ 386,522 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.33/sh−70$583→ 388,243 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.34/sh−157$1,309→ 388,086 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.58/sh−436$3,741→ 384,599 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.30/sh−162$1,345→ 388,498 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.54/sh−261$2,229→ 386,261 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.57/sh−337$2,888→ 385,035 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.28/sh−192$1,590→ 388,695 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.50/sh−572$4,862→ 386,765 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.63/sh−86$742→ 377,328 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.65/sh−174$1,505→ 377,154 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.55/sh−889$7,601→ 385,372 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.60/sh−7,021$60,381→ 377,578 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.62/sh−129$1,112→ 377,414 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.26/sh−366$3,023→ 388,887 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.45/sh−714$6,033→ 387,337 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.25/sh−976$8,052→ 389,253 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.32/sh−150$1,248→ 388,313 total(indirect: See Footnotes)
Sale
Common Stock, $0.001 par value ("Common Stock")
2004-12-22$8.22/sh−122$1,003→ 390,264 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.23/sh−35$288→ 390,229 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.67/sh−627$5,436→ 376,527 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.51/sh−156$1,328→ 386,609 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.69/sh−296$2,572→ 376,231 total(indirect: See Footnotes)
Sale
Common Stock
2004-12-22$8.70/sh−1,187$10,327→ 375,044 total(indirect: See Footnotes)

Footnotes (4)

[F1]These shares sold were held by Perseus-Soros Partners, LLC, a Delaware limited liability company ("Perseus-Soros Partners").
[F2]These securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, LP, a Delaware limited partnership ("Perseus-Soros") and Perseus-Soros Partners. Perseus-Soros Partners is the general partner of Perseus-Soros. Perseus BioTech Fund Partners, LLC, a Delaware limited liability company ("Perseus Partners") and SFM Participation, L.P., a Delaware limited partnership ("SFM Participation"), are the managing members of Perseus-Soros Partners. Perseus-Soros Partners, Perseus Partners, SFM Participation and SFM AH LLC may be deemed to beneficially own the 375,044 shares directly beneficially owned by Perseus-Soros after the transactions reported herein and in the other Form 4's filed by the reporting persons on December 23, 2004.
[F3]SFM AH LLC, a Delaware limited liability company ("SFM AH"), is the general partner of SFM Participation.
[F4]Pursuant to Rule 16a-1(a)(2)(ii)(B) under the Securities Exchange Act of 1934, as amended (the "Act"), Perseus-Soros Partners, Perseus Partners, SFM Participation and SFM AH are deemed to be beneficial owners of the shares beneficially owned by Perseus-Soros or Perseus-Soros Partners only to the extent of the greater of its respective direct or indirect interest in the profits or capital account of Perseus-Soros or Perseus-Soros Partners. Pursuant to Rule 16a-1(a)(4) under the Act, this filing shall not be deemed an admission that Perseus-Soros Partners, Perseus Partners, SFM Participation or SFM AH is, for purposes of Section 16 of the Act or otherwise, the beneficial owner of any securities owned by Perseus-Soros or Perseus-Soros Partners in excess of such amount.

Documents

1 file

4
form4-pspllc122204_bioex.xmlPrimary
FORM 4

Issuer

BIOENVISION INC

CIK 0001028205

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001028205

Filing Metadata

Form type: 4
Filed: Dec 22, 7:00 PM ET
Accepted: Dec 23, 12:35 PM ET
Size: 58.8 KB

View on SEC.gov